Comparative Pharmacology
Head-to-head clinical analysis: LUNESTA versus ZOLPIDEM TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUNESTA versus ZOLPIDEM TARTRATE.
LUNESTA vs ZOLPIDEM TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonbenzodiazepine hypnotic that binds to GABA-A receptors at the benzodiazepine binding site, enhancing GABAergic inhibitory neurotransmission.
Zolpidem is a non-benzodiazepine hypnotic that binds selectively to the benzodiazepine-1 (BZ1) receptor subtype of the GABA-A receptor complex, potentiating GABAergic inhibition. This results in sedative, hypnotic, and anxiolytic effects.
1 mg, 2 mg, or 3 mg orally once immediately before bedtime; not to exceed 3 mg/day.
10 mg orally once daily immediately before bedtime for adults; maximum dose 10 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 6 hours in young adults and about 9 hours in elderly patients. This supports once-nightly dosing for insomnia.
Terminal elimination half-life is approximately 2.5 hours (range 1.4–4.5 hours) in healthy adults; prolonged to about 2.9–4.5 hours in elderly and up to 9.9 hours in hepatic impairment. Clinical context: short half-life minimizes next-day sedation; accumulation unlikely with once-daily dosing.
Primarily hepatic metabolism via CYP3A4 and CYP2E1; renal excretion of metabolites accounts for approximately 80% of total clearance, with about 2-4% excreted unchanged in urine. Fecal excretion contributes less than 10%.
Renal (approximately 80% as metabolites, <1% unchanged), fecal (approximately 16%), biliary (minor).
Category C
Category A/B
Non-Benzodiazepine Hypnotic
Non-Benzodiazepine Hypnotic